Posted by Michael Wonder on 25 Jun 2020
Cancer patients to benefit from new histology independent treatment
25 June 2020 - Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund.
As a histology independent treatment, entrectinib targets all solid tumours that have a certain genetic mutation (a neurotrophic tyrosine receptor kinase gene fusion), regardless of where the cancer originated in the body.
This is particularly beneficial to patients with some rare types of cancer where the treatments are currently limited.
